# IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Source: https://onco.cc/trials/nct07198841/  
OnCo record `nct07198841` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fulzerasib and cetuximab in lung cancer, run by Guangdong Association of Clinical Trials, now recruiting.

## Summary

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation is a phase 2, interventional study registered as NCT07198841 by Guangdong Association of Clinical Trials, with a registry enrolment figure of 48 participants, started 2025-11-03 and due to reach its primary completion in 2027-09. Interventions recorded: IBI351 combined with cetuximab β. Conditions listed: Lung Cancer (Non-Small Cell). Primary outcome: Objective Response Rate. Lung eligibility wording from the registry: "Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB/IIIC), metastatic, or recurrent (Stage IV) non-small cell lung cancer (NSCLC), per the International Association for the Study of Lung Cancer (IASLC) and American Joint Committee on Cancer (AJCC) 8th edition TNM stag". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07198841
- Phase: 2
- Setting: The Efficacy and Safety of IBI351 Plus Cetuximab β in Untreated, Locally Advanced or Metastatic Non-small Cell Lung Cancer With KRAS G12C Mutation: A Single-arm, Prospective, Multicenter Phase II Clinical Study
- Sponsor: Guangdong Association of Clinical Trials
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT07198841: https://clinicaltrials.gov/study/NCT07198841

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Fulzerasib](https://onco.cc/drugs/fulzerasib/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07198841.json